Flourishing innovation in KRAS targeting: Recent advances in medicinal chemistry strategies and future perspectives
Bioorganic Chemistry · 2026
DOI: 10.1016/j.bioorg.2025.109345 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Bioorganic Chemistry, 2026. Verfasst von Tao Shen und 6 weiteren Autor:innen. Beteiligte Einrichtung: College of Biotechnology and Pharmaceutical Engineering, Nanjing Tech University, Nanjing, China. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins p21(ras), Antineoplastic Agents, Neoplasms, Enzyme Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 96 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Special Funds for the Basic Research and Development Program in the Central Non-profit Research Institutes of China, National Key Research and Development Program of China.
Abstract (Originalsprache)
The Kirsten rat sarcoma viral oncogene homolog (KRAS), one of the most frequently mutated oncogenes in human cancers, has long been regarded as an "undruggable" target due to its smooth protein surface and high affinity for GTP. The landmark approval of Sotorasib in 2021, the first covalent KRASG12C inhibitor, shattered this dogma, ushering in a new era of targeted therapy for KRAS-mutant cancers, which also has catalyzed an explosion of innovative strategies extending far beyond covalent G12C targeting. This work highlight reviewed the diverse medicinal chemistry methodologies employed in the development of KRAS-targeted therapeutics. Key strategies discussed include the design of direct inhibitors for specific mutant subtypes (including KRASG12C, KRASG12D, and pan-RAS), indirect inhibitors strategy, molecular glue technology, PROTAC strategies, and combination dosing regimens. Additionally, it encompasses structure-activity relationship (SAR) investigations and activity optimization processes and pharmacokinetic properties studies of representative molecules. Furthermore, we critically evaluate existing challenges in developing small-molecule KRAS modulators while discussing emerging opportunities in overcoming on-target resistance, aiming to offer valuable insights and perspectives for future research in this rapidly evolving field.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Biotechnology and Pharmaceutical Engineering, Nanjing Tech University, Nanjing, China.
- Department of Cell Biology, School of Basic Medical Sciences, Nanjing Medical University, Nanjing, China. Electronic address: tingtingzhou@njmu.edu.cn.
- College of Biotechnology and Pharmaceutical Engineering, Nanjing Tech University, Nanjing, China. Electronic address: syg2023@njtech.edu.cn.
Förderung
- National Natural Science Foundation of China
- Special Funds for the Basic Research and Development Program in the Central Non-profit Research Institutes of China
- National Key Research and Development Program of China
Zitieren
APA
Shen, T., Fei, W., Hu, Z., Pang, M., Ma, J., Zhou, T., & Shang, Y. (2026). Flourishing innovation in KRAS targeting: Recent advances in medicinal chemistry strategies and future perspectives. Bioorganic Chemistry. https://doi.org/10.1016/j.bioorg.2025.109345
Vancouver
Shen T, Fei W, Hu Z, Pang M, Ma J, Zhou T, et al. Flourishing innovation in KRAS targeting: Recent advances in medicinal chemistry strategies and future perspectives. Bioorganic Chemistry. 2026. doi:10.1016/j.bioorg.2025.109345
BibTeX
@article{Shen2026,
author = {Shen, Tao and Fei, WenJuan and Hu, Zherui and Pang, Miaomiao and Ma, Jiaqi and Zhou, Tingting and Shang, Yanguo},
title = {Flourishing innovation in KRAS targeting: Recent advances in medicinal chemistry strategies and future perspectives},
journal = {Bioorganic Chemistry},
year = {2026},
doi = {10.1016/j.bioorg.2025.109345}
}
EUVIMED